Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced that it has scheduled a webcast for 8:00 p.m. ET today, Wednesday, November 10, 2010 to review the INCB28050 Phase II results being presented today at 5:30 p.m. ET during the 2010 ACR/ARHP Annual Scientific Meeting in Atlanta.

The live webcast can be accessed by going to our website at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the webcast will also be available following the event.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, visit the Company's web site at www.incyte.com.



CONTACT:

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications
302-498-6944

KEYWORDS:   United States  North America  Delaware  Georgia

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.